[Action of the anti-inflammatory agent Lonazolac on experimentally-induced acute inflammation of human skin].

Using two experimental models of acute dermatitis in man, Lonazolac proved to possess dose-dependent anti-inflammatory effects. No untoward side effects were seen even at the higher doses of the drug. The results are consistent with animal studies: In its effect on the acute experimental dermatitis, Lonazolac resembles indomethacin more closely than oxyphenbutazone. It is superior to the comparable anti-inflammatory drugs in its effect on the inflammatory erythema of the skin; in its effect on the inflammatory edema of the skin, it stands between oxyphenbutazone and indomethacin.

RCT Entities:   Population Interventions Outcomes